Compare iShares MSCI ACWI ETF (ACWI) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Dolby Laboratories, Inc. — how do they compare? iShares MSCI ACWI ETF trades at $155.38, while Dolby Laboratories, Inc. trades at $50.44 (market cap $4.66B). The key difference: Dolby Laboratories, Inc. pays a 2.86% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, Dolby Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| ACWI | DLB | |
|---|---|---|
52-Week High | $159.97 | $76.79 |
52-Week Low | $128.32 | $49.31 |
Market Cap | — | $4.66B |
Sector | — | Industrials |
Enterprise Value | — | $4.12B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.
Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.
DLB trades at $49.31, down 3.6% today, with technical indicators showing bearish momentum. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.37 versus $1.31 expected. Revenue remains stable at $1.35B for 2025, with robust gross margins of 87.44%. Recent developments include FDA progress for zervimesine in DLB psychosis and recognition as GM's 2025 Supplier of the Year.
Despite near-term technical weakness, DLB's patent-protected revenue streams and high profitability support long-term value. The consensus price target of $87.50 implies significant upside, but investors face risks from cyclical end-markets and potential dilution from drug development. The stock presents a contrarian opportunity with 47% analyst buy ratings amid current bearish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
